State Medicaid Pharmacy & Therapeutics Committee Meeting
Notice Tags
Medicaid, Pharmacies
Notice Type(s)
Meeting
Event Start Date & Time
October 15, 2015 07:00 AM
Event End Date & Time
October 15, 2015 08:30 AM
Event Deadline Date & Time
10/08/15 06:00 PM
Description/Agenda
AGENDA
Utah Department of Health
Pharmacy and Therapeutics Committee
Thursday, October 15, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128
Please note that persons who wish to address the P&T Committee may contact Bryan S. Larson at (bslarson@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, will be limited to 3 minutes due to time constraints.
1) Welcome and Introductions - Clinton Sheffield, MD, Chair
a) Review and Approval of Minutes
b) Housekeeping
2) DUR Board Update - Robyn Seely, PharmD
3) September Reviews:
a) Immune Globulin Agents - Melissa Archer, PharmD
b) Bivigam, Carimune NF, Flebogamma, Flebogamma DIF, GamaSTAN S/D, Gammagard, Gammagard S/D, Gammagard S/D Less IgA, Gammaked, Gammaplex, Gamunex-C, Hizentra, Hizentra 20%, Octagam, Privigen
c) Other States Report - Bryan S. Larson, PharmD
i) Public Comment
(1) Grifols - John S. Cheppo
(2) Baxalta - John E. Sandstrom, PharmD
ii) Board Discussion/Questions
iii) Board Action
4) Next Meeting November 19, 2015 (Ophthalmic blockers and cholinergic agents)
5) Adjourned - Clinton Sheffield, MD, Chair
Public comment that responds to the materials presented by the College of Pharmacy at University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah, College of Pharmacy, and are posted in advance on the P&T Committee website. Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:
Dr. Gary Oderda
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820
All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Tentative 2015- 2016 Pharmacy & Therapeutics Committee Schedule
Month Topic Agents
10/15/2015 Immune Globulin Agents Bivigam, Carimune NF, Flebogamma, Flebogamma DIF, GamaSTAN S/D, Gammagard, Gammagard S/D, Gammagard S/D Less IgA, Gammaked, Gammaplex, Gamunex-C, Hizentra, Hizentra 20%, Octagam, Privigen
11/19/2015 Ophthalmic Beta-Adrenergic Antagonists Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol and all combination agents
Ophthalmic Cholinergic Agonists Acetylcholine, Carbachol, Pilocarpine
12/17/2015 Ophthalmic Muscarinic Antagonists Atropine, Scopolamine, Homatropine, Cyclopentolate, Tropicamide
Ophthalmic Miscellaneous Agents TBD
1/21/2016 Beta-Lactams/Clavulanate Combos Amoxicillin, Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Penicillin, Piperacillin, Piperacillin/Tazobactam, Ticarcillin/Clavulanate
Notice of Special Accommodations (ADA)
NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Bryan Larson at 801-538-6317.